DK1261601T3 - Substituerede indoler til modulering af NFKB-aktivitet - Google Patents
Substituerede indoler til modulering af NFKB-aktivitetInfo
- Publication number
- DK1261601T3 DK1261601T3 DK00974405T DK00974405T DK1261601T3 DK 1261601 T3 DK1261601 T3 DK 1261601T3 DK 00974405 T DK00974405 T DK 00974405T DK 00974405 T DK00974405 T DK 00974405T DK 1261601 T3 DK1261601 T3 DK 1261601T3
- Authority
- DK
- Denmark
- Prior art keywords
- substituted indoles
- nfkb activity
- modulating nfkb
- modulating
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19951360A DE19951360A1 (de) | 1999-10-26 | 1999-10-26 | Substituierte Indole |
| PCT/EP2000/010210 WO2001030774A1 (de) | 1999-10-26 | 2000-10-17 | Substituierte indole zur modulierung von nfkb-aktivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1261601T3 true DK1261601T3 (da) | 2009-11-16 |
Family
ID=7926798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00974405T DK1261601T3 (da) | 1999-10-26 | 2000-10-17 | Substituerede indoler til modulering af NFKB-aktivitet |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20030119820A1 (sr) |
| EP (1) | EP1261601B1 (sr) |
| JP (1) | JP3843012B2 (sr) |
| KR (1) | KR100795709B1 (sr) |
| CN (1) | CN1172929C (sr) |
| AT (1) | ATE437867T1 (sr) |
| AU (1) | AU781553B2 (sr) |
| BR (1) | BR0015026B1 (sr) |
| CA (1) | CA2389165C (sr) |
| CY (1) | CY1110521T1 (sr) |
| CZ (1) | CZ304885B6 (sr) |
| DE (2) | DE19951360A1 (sr) |
| DK (1) | DK1261601T3 (sr) |
| EE (1) | EE05036B1 (sr) |
| ES (1) | ES2329871T3 (sr) |
| HK (1) | HK1049671A1 (sr) |
| HR (1) | HRP20020357B1 (sr) |
| HU (1) | HU229215B1 (sr) |
| IL (2) | IL149272A0 (sr) |
| ME (1) | ME00434B (sr) |
| MX (1) | MXPA02003998A (sr) |
| NO (1) | NO323952B1 (sr) |
| NZ (1) | NZ518587A (sr) |
| PL (1) | PL200115B1 (sr) |
| PT (1) | PT1261601E (sr) |
| RS (1) | RS50424B (sr) |
| RU (1) | RU2255087C2 (sr) |
| SI (1) | SI1261601T1 (sr) |
| SK (1) | SK287116B6 (sr) |
| TR (1) | TR200201144T2 (sr) |
| WO (1) | WO2001030774A1 (sr) |
| ZA (1) | ZA200203204B (sr) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK288019B6 (sk) | 1999-12-24 | 2012-11-05 | Aventis Pharma Limited | Azaindoles derivatives, their use and pharmaceutical composition containing thereof |
| NZ525474A (en) | 2000-10-26 | 2005-10-28 | Tularik Inc | Antiinflammation agents |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| EP1417200B1 (en) * | 2001-08-13 | 2010-06-02 | E.I. Du Pont De Nemours And Company | Substituted 1h-dihydropyrazoles, their preparation and use |
| EP1443927B1 (en) * | 2001-11-07 | 2007-01-10 | Millennium Pharmaceuticals, Inc. | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma |
| US7176314B2 (en) | 2001-12-05 | 2007-02-13 | Amgen, Inc. | Inflammation modulators |
| EP1474425B9 (en) | 2002-01-07 | 2008-07-02 | Eisai Co., Ltd. | Deazapurines and uses thereof |
| US6974870B2 (en) | 2002-06-06 | 2005-12-13 | Boehringer Ingelheim Phamaceuticals, Inc. | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| AU2003237330A1 (en) | 2002-06-06 | 2003-12-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
| US7462638B2 (en) * | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| WO2004041285A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP1462105A1 (en) * | 2003-03-28 | 2004-09-29 | Procorde GmbH | Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases |
| BRPI0409263A (pt) * | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
| US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| DK1718608T3 (da) | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
| KR20070014166A (ko) | 2004-04-09 | 2007-01-31 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료에 유용한 베타-카르볼린 |
| US7425580B2 (en) | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| WO2007005534A2 (en) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
| US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| JP2009001495A (ja) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体 |
| JP2009539865A (ja) | 2006-06-06 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用 |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| US8193237B2 (en) * | 2007-01-15 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | Indole derivative having IκB kinase β inhibitory activity |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EP2314575B1 (en) * | 2008-07-14 | 2013-06-19 | Santen Pharmaceutical Co., Ltd | Novel indole derivative having carbamoyl group, ureido group and substituted oxy group |
| MD4009C2 (ro) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos |
| EP2366699B1 (en) | 2008-10-02 | 2013-08-07 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| KR101708512B1 (ko) * | 2008-10-23 | 2017-02-20 | 가부시키가이샤 야쿠르트 혼샤 | 페난트로인돌리지딘 유도체 및 이것을 유효 성분으로 하는 ＮＦκＢ 저해제 |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010096751A1 (en) * | 2009-02-23 | 2010-08-26 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| KR20130099044A (ko) | 2010-08-12 | 2013-09-05 | 사노피 | ２，３디아미노프로피온산 유도체의 에난티오머 형태의 제조 방법 |
| CN102584842A (zh) * | 2011-01-17 | 2012-07-18 | 北京大学 | 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途 |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN106999535B (zh) * | 2014-09-26 | 2021-12-21 | 拉金德拉·萨哈伊·巴特纳格尔 | 用于治疗疾病和病症的NFκB活性的抑制剂 |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| AU2018392316B2 (en) * | 2017-12-19 | 2022-05-12 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as TLR inhibitors |
| US20210236398A1 (en) * | 2020-01-31 | 2021-08-05 | L'oreal | Compositions and methods for hair |
| FR3107832B1 (fr) * | 2020-03-05 | 2022-04-29 | Oreal | Compositions et procédés pour les cheveux |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0664792B1 (en) * | 1992-10-14 | 2000-01-05 | Merck & Co. Inc. | Fibrinogen receptor antagonists |
| GB9225141D0 (en) * | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
| JP3213426B2 (ja) * | 1993-02-19 | 2001-10-02 | エーザイ株式会社 | ６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体 |
| IT1271352B (it) * | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| GB9605065D0 (en) * | 1996-03-11 | 1996-05-08 | Merck Sharp & Dohme | Therapeutic agents |
| FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
| AU3767997A (en) * | 1996-08-01 | 1998-02-25 | Merckle Gmbh | Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
| KR20000057137A (ko) * | 1996-11-19 | 2000-09-15 | 스티븐 엠. 오드레 | 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제 |
| CA2309319A1 (en) * | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
| TR200002447T2 (tr) * | 1998-02-25 | 2000-11-21 | Genetics Institute, Inc. | Fosfolinaz enzimlerinin inhibitörleri |
| NZ516348A (en) * | 1999-06-23 | 2003-06-30 | Aventis Pharma Gmbh | Substituted benzimidazole |
| US7462638B2 (en) | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| RU2006143758A (ru) | 2004-05-12 | 2008-06-27 | Авентис Фармасьютикалз Инк. (Us) | По существу чистая 2-{[2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбонил]-амино}-3-(фенилпиридин-2-иламино)-пропионовая кислота в качестве ингибитора 1кв киназы |
-
1999
- 1999-10-26 DE DE19951360A patent/DE19951360A1/de not_active Withdrawn
-
2000
- 2000-10-17 JP JP2001533128A patent/JP3843012B2/ja not_active Expired - Fee Related
- 2000-10-17 WO PCT/EP2000/010210 patent/WO2001030774A1/de active IP Right Grant
- 2000-10-17 SI SI200031041T patent/SI1261601T1/sl unknown
- 2000-10-17 TR TR2002/01144T patent/TR200201144T2/xx unknown
- 2000-10-17 EP EP00974405A patent/EP1261601B1/de not_active Expired - Lifetime
- 2000-10-17 RS YUP-217/02A patent/RS50424B/sr unknown
- 2000-10-17 DE DE50015700T patent/DE50015700D1/de not_active Expired - Lifetime
- 2000-10-17 DK DK00974405T patent/DK1261601T3/da active
- 2000-10-17 PT PT00974405T patent/PT1261601E/pt unknown
- 2000-10-17 NZ NZ518587A patent/NZ518587A/en not_active IP Right Cessation
- 2000-10-17 CA CA2389165A patent/CA2389165C/en not_active Expired - Fee Related
- 2000-10-17 MX MXPA02003998A patent/MXPA02003998A/es active IP Right Grant
- 2000-10-17 HU HU0203228A patent/HU229215B1/hu not_active IP Right Cessation
- 2000-10-17 ME MEP-2008-655A patent/ME00434B/me unknown
- 2000-10-17 CN CNB008144729A patent/CN1172929C/zh not_active Expired - Fee Related
- 2000-10-17 AU AU12728/01A patent/AU781553B2/en not_active Ceased
- 2000-10-17 IL IL14927200A patent/IL149272A0/xx active IP Right Grant
- 2000-10-17 KR KR1020027005395A patent/KR100795709B1/ko not_active IP Right Cessation
- 2000-10-17 AT AT00974405T patent/ATE437867T1/de active
- 2000-10-17 RU RU2002113651/04A patent/RU2255087C2/ru not_active IP Right Cessation
- 2000-10-17 BR BRPI0015026-6A patent/BR0015026B1/pt not_active IP Right Cessation
- 2000-10-17 SK SK543-2002A patent/SK287116B6/sk not_active IP Right Cessation
- 2000-10-17 PL PL354528A patent/PL200115B1/pl unknown
- 2000-10-17 ES ES00974405T patent/ES2329871T3/es not_active Expired - Lifetime
- 2000-10-17 EE EEP200200217A patent/EE05036B1/xx not_active IP Right Cessation
- 2000-10-17 CZ CZ2002-1413A patent/CZ304885B6/cs not_active IP Right Cessation
-
2002
- 2002-04-17 NO NO20021808A patent/NO323952B1/no not_active IP Right Cessation
- 2002-04-22 IL IL149272A patent/IL149272A/en not_active IP Right Cessation
- 2002-04-23 ZA ZA200203204A patent/ZA200203204B/en unknown
- 2002-04-24 HR HR20020357A patent/HRP20020357B1/xx not_active IP Right Cessation
- 2002-10-04 US US10/263,691 patent/US20030119820A1/en not_active Abandoned
-
2003
- 2003-03-14 HK HK03101851A patent/HK1049671A1/xx not_active IP Right Cessation
-
2004
- 2004-05-11 US US10/842,427 patent/US20040209868A1/en not_active Abandoned
-
2005
- 2005-07-22 US US11/187,396 patent/US7342029B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 CY CY20091101115T patent/CY1110521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1261601T3 (da) | Substituerede indoler til modulering af NFKB-aktivitet | |
| DE50010931D1 (de) | Substituierte benzimidazole | |
| DK0946507T3 (da) | Substituerede pyrrolylforbindelser til behandling af inflammation | |
| DK0882021T3 (da) | Nye phenanthridiner | |
| DE59709414D1 (de) | Oxyiminopregnancarbolactone | |
| MY140074A (en) | INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkB KINASE | |
| AR023777A1 (es) | Nuevos compuestos | |
| IT1285770B1 (it) | Composti corticoidei | |
| DE60028010D1 (de) | Verminderung des haarwuchses | |
| UY25712A1 (es) | Benzamidas sustituidas y su aplicación en medicamentos | |
| SE9802208D0 (sv) | Novel compounds | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
| SE9802209D0 (sv) | Novel compounds | |
| ECSP003590A (es) | Compuestos calcioliticos | |
| SE9504662D0 (sv) | New compounds | |
| DE69828638D1 (de) | Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität | |
| SE9802207D0 (sv) | Novel compounds | |
| DE69804843D1 (de) | Heterozyklische verbidungen mit mmp und tnf inhibitorisher wirkung | |
| SU1732642A1 (ru) | 4-хлоранилид n-ацетил-n-аллилантраниловой кислоты, проявляющий противовоспалительную и анальгетическую активность |